Remote user testing for medical device development: advantages as well as challenges abound
What failure rate are we willing to accept in cell therapy manufacture? Insights from medical device development
Biomimetics evolution at the micron scale and beyond
Special Delivery: can advanced intracellular delivery enable superior cell therapies for solid tumour treatment – and beyond?
Inspired by the promise of CAR-T cell therapy, new technologies to combat the hostile solid tumour microenvironment are being developed, underpinned by innovations in intracellular delivery, say Megan McCandless and Stuart Lowe.
Only a ‘click’ away: click chemistry transforms life science applications
Click chemistry has come into its own in a wide range of life science applications and opens up opportunities that lie between chemistry, biology and material science, says Wenshu Xu.
Accelerating medical device development: Lessons from CoVent and the UK ventilator challenge
Developing a medical device in weeks rather than years during the coronavirus pandemic was an extraordinary undertaking. Dan Strange reviews TTP’s “Project Jarre” to develop the CoVent(TM) ventilator and draws some lessons as to how – when needs must – faster medical device development is possible.
DNA Origami: What can we make of it?
From smiley faces to diagnostic sensors, the possibility of using DNA as a nanofabrication material is gaining increasing attention. Gary Skinner explains “DNA Origami,” its applications and what is holding back its wider adoption into the marketplace.
Key early-stage microfabrication decisions for life science start-ups and SMEs
Many companies face important early-stage decisions about how best to access cleanroom and laboratory facilities, equipment and know-how towards microfabrication – get these decisions wrong and progress to market can become painfully slow, says Fred Hussain.
Spotlight on upconversion nanoparticles: finding the right chemistry to make life science applications “click”
Biomedical imaging and diagnostic platforms increasingly demand stable detection reagents and quantifiable signal output. Upconversion nanoparticles fit the bill and, in the hands of Wenshu Xu and Verity Jackson, allow for multiplex biomarker detection.
Complex generics pharmaceutical devices: scaling the barriers to entry
Many generics companies have experienced the challenges of getting a “complex generic” to market firsthand. But, argues David Cottenden, there are device strategies to stack the odds in your favour…
Imaging by the numbers: quantitative imaging for digital pathology
Pathology is going digital and novel quantitative imaging approaches will take diagnostic power to the next level while creating opportunities for automation in the multi-billion tissue diagnostics industry. Alexander Carr reviews steps towards quantification in 2019.
How to develop microfluidics for commercial products
Whilst microfluidic devices have huge potential, most fail to progress beyond research use, let alone reach mass consumer markets similar to products in the microelectronics industry. But developers are increasingly using cycles of (1) optimised designs, (2) apt manufacturing, and (3) robust testing to create highly integrated and compact devices with exciting functionality for widespread application.
What is a good innovation strategy in surgery… and is it robotics?
Robotic surgery is a hot topic: the concept is popular with patients, on the minds of industry leaders, and seen as the future of surgery by many investors. Too often, robotic-assisted surgery is equated with precision, and precision with improved clinical outcomes. Excitement is driving investment and a growing number of robotic-assisted surgery companies. But, in basic terms, what is a good innovation strategy in surgery… and is it robotics?